Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

Identifying stocks to buy and hold for decades rather than months or years can be difficult. The world and the economy are ...